Charles River Laboratories International P/E Ratio

The latest P/E ratio for CRL is -57.86. That is below the Healthcare sector average of 26.36. Investors often review this figure alongside Charles River Laboratories International's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CRL currently prints -57.86 for P/E ratio, while the sector average sits near 26.36. That is roughly 319.5% below the sector mean. Large gaps often invite a closer look at Charles River Laboratories International's growth, margins, and balance sheet.

A P/E ratio of -57.86 for Charles River Laboratories International is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with CRL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CRL's P/E ratio (-57.86), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Charles River Laboratories International's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.